New information is available regarding more recently approved antipsychotics, as well as studies examining the risk of metabolic abnormalities in patients with schizophrenia. This session will focus on factors related to metabolic health in patients with schizophrenia. New findings regarding the propensity of second-generation antipsychotics to be associated with weight gain and metabolic abnormalities, as well as interventions designed to reduce weight gain and/or metabolic abnormalities, will be discussed.
